CorMedix reports preliminary Q4 2024 net revenue ~$31M, FY ~$43M; Q4 Adj EBITDA >$12M

CorMedix Inc.

2024-FY EPS reported -$0.30 revenue$43,472,170

Q4 2024 prelim unaudited net revenue ~$31M; FY 2024 ~$43M; Q4 Adj EBITDA >$12M.
Open purchase orders >$25M for Q1 2025 delivery; shipping DefenCath to all three MDO customers.
LDO implementation targeted H1 2025; aims for 4,000 patients in H2 2025.
Expanded inpatient deployment with Syneos Health in Q1 2025; field team reorganized, some roles eliminated.
FY 2025 opex guidance $72-78M (excl non-cash/one-time); cash & investments ~$52M at Dec 31, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.